查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1970996

沙眼治疗市场－全球产业规模、份额、趋势、机会、预测：按给药途径、药物类别、地区和竞争格局划分，2021-2031年

Trachoma Treatment Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Route of Administration (Oral, and Topical), By Drug Class (Macrolides, Tetracycline, Ophthalmic Anti-infective), By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 181 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球沙眼治疗市场预计将从 2025 年的 6.574 亿美元成长到 2031 年的 10.2995 亿美元，复合年增长率为 7.77%。

该市场专注于提供治疗性介入和外科手术，主要使用阿奇霉素等抗生素治疗披衣菌感染衣原体感染疾病和矫正睑内翻（睫毛向内翻转）。该行业的主要驱动力是协调实施SAFE策略和强有力的国际药品捐赠计划，这些计划能够实现大规模用药。事实上，根据国际沙眼预防联盟（ICTC）的数据，到2024年，将有4,440万人接受沙眼抗生素治疗。

市场概览
预测期 2027-2031
市场规模：2025年 6.574亿美元
市场规模：2031年 1,029,950,000 美元
复合年增长率：2026-2031年 7.77%
成长最快的细分市场 口服
最大的市场 北美洲

然而，限制市场扩张的一大障碍是向偏远和受衝突影响地区分发治疗药物的物流复杂性。在这些高发地区，基础设施不足和当地局势动盪经常扰乱医疗供应链，阻碍外科手术团队的部署，并有效地延缓了彻底根除疾病的努力。

市场驱动因素

随着各国加速实现2030年根除沙眼目标的步伐，世卫组织SAFE策略的协调实施在市场拓展中发挥关键促进者。这个综合框架结合了手术、抗生素、脸部卫生和环境改善，要求在流行地区进行广泛的干预措施，并刺激对外科耗材和治疗性抗生素的需求。同时，各国政府正优先进行严格的检测，以确认持续的低盛行率，从而推动检验工作。这些协调努力的成效显而易见，世卫组织2024年10月发布的《沙眼概况介绍》确认，已有20个国家被认定为已根除沙眼这一公共卫生问题。

策略性的企业药品捐赠和国际非政府组织的持续资助，透过确保阿奇霉素和营运资源的稳定供应，进一步维护了市场稳定。在政府预算不足的低收入地区，公私伙伴关係对于维持大规模药物管理计画至关重要，能够有效弥合临床需求与商业性供应之间的差距。辉瑞公司于2024年3月发布的《2023年影响报告》充分体现了这种支持的规模，该报告详细介绍了公司向国际沙眼预防组织（ITI）捐赠其第10亿剂希舒美（Zithromax）的情况。考虑到世界卫生组织（WHO）报告称，到2024年，仍有约1.03亿人居住在需要沙眼预防的地区，这项捐赠意义重大。

市场挑战

将治疗药物运送到偏远和受衝突影响地区的物流挑战，直接限制了全球沙眼治疗市场的成长，因为这切断了供应与患者需求之间的关键连结。由于该市场从根本上依赖大规模药物管理（MDA）宣传活动和流动手术营，一旦实际通道中断，服务提供就会立即停止。此外，不稳定地区的基础设施不足和安全问题也阻碍了医护人员和抗生素的部署。这些障碍有效地缩小了市场规模，导致现有治疗资源无法在最迫切需要的地区得到利用。

因此，这种运作瓶颈导致大量高风险族群无法得到治疗，儘管有捐赠药品，但防治工作仍停滞不前。这种可近性问题的严重性使得市场无法弥合潜在需求与实际供应之间的差距，情况十分严峻。世界卫生组织（世卫组织）的研究显示，截至2025年4月，约有1.026亿人居住在沙眼流行地区，需要接受介入治疗。这项数据表明，市场很大一部分仍然面临物流上的障碍，阻碍了根除策略的全面实施。

市场趋势

智慧型手机数位诊断工具的普及应用正在从根本上改变全球沙眼治疗市场，使活跃性行为感染丛集的识别和追踪更加现代化。由于传统的纸本调查在即时决策方面效率低下，相关人员正在整合行动医疗应用程序，利用演算法严重程度评估和GPS定位技术，实现高精度的流行率地图绘製。这使得抗生素治疗方法能够迅速部署到疫情热点地区。 Sightsavers于2025年7月发布的2024财年年度报告详细记录了这项营运现代化的规模，其中包括990万次眼科检查。该数位平台透过简化偏远地区的患者追踪和报告流程，正在扩大服务范围。

同时，随着越来越多的国家将活跃感染病例降至公共卫生关注阈值以下，市场正向经过检验的监测策略转型。这一趋势正推动大规模药物管理（MDA）宣传活动向有针对性的监测通讯协定转变，以便检测并快速应对疾病復发，对专业诊断培训和永续监测框架的需求远高于大规模抗生素采购。为了凸显这项转变的迫切性，国际抗击沙眼联盟（ICTC）于2025年4月发布的《2025年差距分析报告》指出，又有五个国家实现了其根除沙眼的盛行率目标。这表明市场正发生重大转变，需要为稳健的、经过检验的监测系统提供资金筹措并进行开发，以巩固这些成果。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球沙眼治疗市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 给药途径（口服、局部）
    • 药物分类（大环内酯类、四环霉素、眼用抗感染药）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美沙眼治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲沙眼治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区沙眼治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲沙眼治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲沙眼治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球沙眼治疗市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Novartis AG
  • Gilead Sciences Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • BioCryst Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Boehringer Ingelheim GmBH
  • Pfizer, Inc.
  • Sanofi AG
  • Janssen Pharmaceutical, Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 23821

The Global Trachoma Treatment Market is projected to expand from USD 657.40 Million in 2025 to USD 1029.95 Million by 2031, reflecting a compound annual growth rate of 7.77%. This market focuses on providing therapeutic interventions, primarily antibiotics such as azithromycin and surgical procedures, to address infections caused by Chlamydia trachomatis and correct trichiasis. The industry is principally driven by the coordinated execution of the SAFE strategy and robust international drug donation programs that enable mass drug administration; indeed, the International Coalition for Trachoma Control reported that 44.4 million individuals received antibiotic treatment for trachoma in 2024.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 657.40 Million
Market Size 2031USD 1029.95 Million
CAGR 2026-20317.77%
Fastest Growing SegmentOral
Largest MarketNorth America

However, a major obstacle limiting market reach is the logistical complexity of distributing treatments to remote and conflict-affected regions. In these high-prevalence areas, infrastructure deficits and regional instability frequently disrupt medical supply chains and impede the deployment of surgical teams, effectively stalling efforts to achieve complete disease eradication.

Market Driver

The coordinated implementation of the WHO SAFE strategy acts as the primary catalyst for market advancement as nations accelerate efforts to meet 2030 elimination targets. This comprehensive framework, which combines surgery, antibiotics, facial cleanliness, and environmental improvement, mandates extensive interventions in endemic zones and fuels the demand for surgical consumables and therapeutic antibiotics, while governments prioritize validation processes through rigorous testing to confirm sustained low prevalence. The success of these structured efforts is evident, as the World Health Organization's 'Trachoma' fact sheet from October 2024 confirms that 20 countries have been validated for eliminating trachoma as a public health problem.

Strategic corporate drug donations and persistent funding from international non-governmental organizations further underpin market stability by ensuring a reliable supply of azithromycin and operational resources. These initiatives are essential for maintaining mass drug administration schedules in low-income regions where government budgets are often insufficient for procurement, with public-private partnerships effectively bridging the gap between clinical needs and commercial affordability. The scale of this support is highlighted by Pfizer's '2023 Impact Report' from March 2024, which noted the donation of the company's 1 billionth dose of Zithromax to the International Trachoma Initiative, a vital contribution given that the World Health Organization reported approximately 103 million people still lived in areas requiring trachoma interventions in 2024.

Market Challenge

The logistical difficulty of transporting treatments to remote and conflict-affected regions directly restricts the growth of the Global Trachoma Treatment Market by severing the critical link between supply and patient demand. Because the market relies fundamentally on Mass Drug Administration (MDA) campaigns and mobile surgical camps, any disruption to physical access immediately halts service delivery, while infrastructure deficits and safety concerns in unstable regions prevent the deployment of medical personnel and antibiotics. These barriers effectively reduce the actionable market size, rendering available therapeutic resources unusable in the areas where they are most urgently needed.

Consequently, this operational bottleneck leaves a vast segment of the at-risk population untreated, stalling progress despite the availability of donated medications. The magnitude of this inaccessibility prevents the market from closing the gap between potential demand and actual provision, a situation underscored by the World Health Organization's finding that, as of April 2025, approximately 102.6 million people resided in trachoma-endemic areas requiring interventions. This statistic emphasizes that a massive portion of the market remains logistically out of reach, preventing the complete execution of elimination strategies.

Market Trends

The adoption of smartphone-based digital diagnostic tools is fundamentally reshaping the Global Trachoma Treatment Market by modernizing the identification and tracking of active infection clusters. As traditional paper-based surveys prove inefficient for real-time decision-making, market stakeholders are integrating mobile health applications that utilize algorithm-based grading and GPS tagging to map prevalence with high precision, allowing for the rapid deployment of antibiotic regimens to micro-hotspots. The scale of this operational modernization is illustrated by Sightsavers' 'Annual Report 2024' from July 2025, which details 9.9 million eye examinations, a volume of service delivery increasingly enabled by digital platforms that streamline patient tracking and reporting in remote areas.

Simultaneously, the market is undergoing a transition to post-validation surveillance and monitoring strategies as more nations suppress active transmission below the threshold of public health concern. This trend necessitates a pivot from large-scale Mass Drug Administration (MDA) campaigns to targeted surveillance protocols designed to detect and rapidly respond to disease recrudescence, driving demand for specialized diagnostic training and sustainable monitoring frameworks rather than bulk antibiotic procurement. Highlighting the urgency of this transitional phase, the International Coalition for Trachoma Control's '2025 ICTC Gaps Analysis Report' from April 2025 notes that five countries have newly achieved prevalence targets for elimination, signaling a critical market shift toward funding and equipping robust pre-validation surveillance systems to secure these gains.

Key Market Players

  • Novartis AG
  • Gilead Sciences Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • BioCryst Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Boehringer Ingelheim GmBH
  • Pfizer, Inc.
  • Sanofi A.G.
  • Janssen Pharmaceutical, Inc.

Report Scope

In this report, the Global Trachoma Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Trachoma Treatment Market, By Route of Administration

  • Oral
  • Topical

Trachoma Treatment Market, By Drug Class

  • Macrolides
  • Tetracycline
  • Ophthalmic Anti-infective

Trachoma Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Trachoma Treatment Market.

Available Customizations:

Global Trachoma Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Trachoma Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Route of Administration (Oral, Topical)
    • 5.2.2. By Drug Class (Macrolides, Tetracycline, Ophthalmic Anti-infective)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Trachoma Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Route of Administration
    • 6.2.2. By Drug Class
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Trachoma Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Route of Administration
        • 6.3.1.2.2. By Drug Class
    • 6.3.2. Canada Trachoma Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Route of Administration
        • 6.3.2.2.2. By Drug Class
    • 6.3.3. Mexico Trachoma Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Route of Administration
        • 6.3.3.2.2. By Drug Class

7. Europe Trachoma Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Route of Administration
    • 7.2.2. By Drug Class
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Trachoma Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Route of Administration
        • 7.3.1.2.2. By Drug Class
    • 7.3.2. France Trachoma Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Route of Administration
        • 7.3.2.2.2. By Drug Class
    • 7.3.3. United Kingdom Trachoma Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Route of Administration
        • 7.3.3.2.2. By Drug Class
    • 7.3.4. Italy Trachoma Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Route of Administration
        • 7.3.4.2.2. By Drug Class
    • 7.3.5. Spain Trachoma Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Route of Administration
        • 7.3.5.2.2. By Drug Class

8. Asia Pacific Trachoma Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Route of Administration
    • 8.2.2. By Drug Class
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Trachoma Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Route of Administration
        • 8.3.1.2.2. By Drug Class
    • 8.3.2. India Trachoma Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Route of Administration
        • 8.3.2.2.2. By Drug Class
    • 8.3.3. Japan Trachoma Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Route of Administration
        • 8.3.3.2.2. By Drug Class
    • 8.3.4. South Korea Trachoma Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Route of Administration
        • 8.3.4.2.2. By Drug Class
    • 8.3.5. Australia Trachoma Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Route of Administration
        • 8.3.5.2.2. By Drug Class

9. Middle East & Africa Trachoma Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Route of Administration
    • 9.2.2. By Drug Class
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Trachoma Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Route of Administration
        • 9.3.1.2.2. By Drug Class
    • 9.3.2. UAE Trachoma Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Route of Administration
        • 9.3.2.2.2. By Drug Class
    • 9.3.3. South Africa Trachoma Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Route of Administration
        • 9.3.3.2.2. By Drug Class

10. South America Trachoma Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Route of Administration
    • 10.2.2. By Drug Class
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Trachoma Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Route of Administration
        • 10.3.1.2.2. By Drug Class
    • 10.3.2. Colombia Trachoma Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Route of Administration
        • 10.3.2.2.2. By Drug Class
    • 10.3.3. Argentina Trachoma Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Route of Administration
        • 10.3.3.2.2. By Drug Class

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Trachoma Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Novartis AG
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Gilead Sciences Inc.
  • 15.3. F. Hoffmann-La Roche Ltd.
  • 15.4. GlaxoSmithKline PLC
  • 15.5. BioCryst Pharmaceuticals, Inc.
  • 15.6. Merck & Co., Inc.
  • 15.7. Boehringer Ingelheim GmBH
  • 15.8. Pfizer, Inc.
  • 15.9. Sanofi A.G.
  • 15.10. Janssen Pharmaceutical, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer